Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics Q4 revenue down to $213.2 million; loss narrows to $65.9 million

Mixed Impact 3 of 5 earnings Written later

PTC Therapeutics reported fourth-quarter and full-year 2024 results. Revenue fell from a year earlier, while the net loss narrowed, with a $99.9 million gain on sale of a priority review voucher offsetting part of a $159.5 million intangible asset impairment. The company guided full-year 2025 total revenue to between $600 million and $800 million.

Key points

  • Q4 2024 total revenue was $213.2 million, versus $307.1 million in Q4 2023; full-year 2024 revenue was $806.8 million, versus $937.8 million in 2023.
  • Q4 2024 net loss was $65.9 million, or $0.85 per share, versus $155.8 million, or $2.06 per share, in Q4 2023.
  • Q4 2024 results include a $159.5 million intangible asset impairment and a $99.9 million gain on sale of a priority review voucher.
  • 2025 guidance: total revenue of $600 million to $800 million; cash, cash equivalents and marketable securities were $1,139.7 million on December 31, 2024.

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:10 PM ET
Accession number0001070081-25-000011

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.